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Using health and 
demographic 
surveillance systems for 
teratovigilance in Africa
Increased funding in the past decade 
has improved healthcare coverage of 
the population and access to vaccines 
and drugs across sub-Saharan Africa.1 
However, there is still a need to 
collect valid and sufficient baseline 
data, data on the safety of drugs and 
vaccines used during pregnancy, 
and for innovative approaches to 
pharmacovigilance in pregnancy to 
inform policy makers and to improve 
treatment guidelines.
Interest in establishing sustainable 
pharmacovigilance systems in Africa 
is gaining momentum thanks to 
plans for large-scale implementation 
of artemisinin-based combination 
therapies across Africa. However, 
less than 1% of individual case safety 
reports in WHO’s database (VigiBase®) 
are from Africa.2
Drugs such as tetracycline, 
m e t r o n i d a z o l e ,  a l b e n d a z o l e , 
mebendazole, and efavirenz are 
not recommended during the first 
trimester because of potential embryo 
toxicity.3 Nonetheless, these drugs are 
still used by women of childbearing 
age, and even pregnant women, 
by self-medication or irrational 
prescriptions. 
A different strategy, such as 
continuous longitudinal follow-up, 
is needed to collect reliable data on 
pregnant women. The health and 
demographic surveillance system 
(HDSS) platform of the INDEPTH 
Network is one such strategy that 
longitudinally documents millions 
of person-years and vital statistics 
relating to individuals in specific 
communities.4 The HDSS can be used 
for pharmacovigilance for the general 
population, but speciﬁ cally for pregnant 
women and other susceptible groups. 
For example, a study in Tanzania used 
an HDSS platform to monitor the 
safety of drugs during pregnancy.5 
More recently, INDEPTH introduced 
CHESS,6 a new generation of population 
surveillance operations that integrates 
across population and health facility 
data systems and links demographic, 
epidemiological, mortality, morbidity, 
clinical, laboratory, household, 
environmental, health systems, and 
other contextual data, with a unique 
electronic individual identification 
system throughout. CHESS will make 
pharmacovigilance more eﬀ ective.
With more than 2 million people 
under longitudinal evaluation in 
African countries, this population 
could generate a suﬃ  cient sample size 
of pregnant women for pharmaco-
epidemiological studies through all 
trimesters. Data collection staff are 
well trained in collecting data from 
sensitive vital events (eg, death, 
abortion, and medication, drug 
or vaccine adverse events). With 
CHESS, a form of enhanced HDSS, 
we could identify the main classes of 
medications used by pregnant women, 
prospectively determine the incidence 
and risk factors of suspected adverse 
events among pregnant women, 
identify and evaluate adverse eﬀ ects 
that are likely to affect compliance 
and treatment outcomes, and, 
finally, demonstrate the feasibility 
of using the HDSS as a sustainable 
platform to assess the use and safety 
of medications to facilitate decision 
making in Africa. 
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